Clinical Indications for Hyperbaric Oxygen Therapy
Hyperbaric Oxygen Therapy for Idiopathic Sudden Sensorineural Hearing Loss
Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) is a rapid loss of hearing that develops over a period of hours to several days without an identifiable cause.
Hyperbaric Oxygen Therapy (HBOT) is recognized by the Undersea & Hyperbaric Medical Society (UHMS) as an accepted treatment for ISSNHL and is generally used in combination with corticosteroid therapy.
Because treatment benefit appears greatest when therapy begins early, sudden sensorineural hearing loss should be considered a time-sensitive condition requiring prompt otolaryngologic and audiologic evaluation.
Clinical Presentation
Why Hyperbaric Oxygen Therapy Is Used
The cochlea has a high metabolic demand and depends on adequate oxygen delivery for normal function. HBOT substantially increases dissolved oxygen within plasma and increases oxygen diffusion into the inner ear.
When Should Hyperbaric Consultation Be Considered?
Early consultation may be appropriate for patients with confirmed idiopathic sudden sensorineural hearing loss, particularly when hearing loss is moderate to profound.
UHMS recommends considering HBOT for patients with moderate to profound ISSNHL who present within approximately 14 days of symptom onset.
The American Academy of Otolaryngology–Head and Neck Surgery states that clinicians may offer HBOT:
- Combined with steroid therapy within 2 weeks of symptom onset as initial treatment
- Combined with steroid therapy within 1 month of symptom onset as salvage treatment
Earlier treatment is generally associated with a greater likelihood of hearing improvement.
HBOT as Part of Multidisciplinary Care
HBOT should be coordinated with appropriate otolaryngologic and audiologic care.
Evaluation and treatment may include:
- Otolaryngologic examination
- Pure-tone audiometry
- Systemic corticosteroids
- Intratympanic corticosteroids
- MRI or other evaluation for retrocochlear pathology
- Follow-up audiometry
- Audiologic rehabilitation for persistent hearing loss
AAO-HNS recommends intratympanic steroid therapy for patients with incomplete recovery approximately 2 to 6 weeks after symptom onset.
HBOT should generally be considered an adjunct to steroid treatment rather than a stand-alone therapy.
Clinical Evidence and Guidelines
Idiopathic sudden sensorineural hearing loss is recognized by the Undersea & Hyperbaric Medical Society as an accepted indication for HBOT.
The American Academy of Otolaryngology–Head and Neck Surgery also identifies HBOT combined with corticosteroids as a treatment option for both initial and salvage therapy within appropriate time windows.
A systematic review and meta-analysis of randomized controlled trials published in JAMA Otolaryngology–Head & Neck Surgery found that HBOT-containing treatment regimens were associated with greater hearing improvement and higher odds of hearing recovery compared with control therapy.
Other meta-analyses have similarly found greater benefit when HBOT is added to standard medical therapy, particularly in patients with severe or profound hearing loss.
Patient selection and early treatment remain important because spontaneous hearing recovery also occurs in some patients with ISSNHL.
Medicare Coverage
Idiopathic sudden sensorineural hearing loss is not included among the nationally covered HBOT conditions under Medicare National Coverage Determination 20.29.
CMS states that HBOT indications not included within its specific covered-condition list are not covered under the Medicare program.
This is an important distinction because ISSNHL is recognized as an HBOT indication by UHMS and as a treatment option by AAO-HNS, but Medicare coverage criteria are separate from clinical guidelines.
Commercial insurance coverage varies by payer and plan.
When to Refer
Consider prompt hyperbaric medicine consultation when a patient has:
- Confirmed sudden sensorineural hearing loss
- Moderate to profound hearing loss
- Recent onset of symptoms
- Incomplete recovery following initial steroid treatment
- Significant unilateral hearing loss affecting function
Referral is most time-sensitive during the first two weeks after symptom onset, although salvage HBOT combined with steroid therapy may be considered within one month.
HBOT should be coordinated with otolaryngologic evaluation and should not delay appropriate diagnostic workup or corticosteroid therapy.
Advance Your Hyperbaric Medicine Training
Explore Hyperbaric Medicine: Principles & Practice, 2nd Edition, a comprehensive 40-hour CME/CEU course designed for physicians, advanced practice providers, nurses, and allied health professionals seeking deeper clinical and operational knowledge in hyperbaric medicine.
References
Undersea & Hyperbaric Medical Society. Hyperbaric Oxygen Therapy Indications: Idiopathic Sudden Sensorineural Hearing Loss.
Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngology–Head and Neck Surgery. 2019;161(1_suppl)–S45.
Joshua TG, Ayub A, Wijesinghe P, Nunez DA. Hyperbaric Oxygen Therapy for Patients With Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. JAMA Otolaryngology–Head & Neck Surgery. 2022;148(1):5–11.
Rhee TM, Hwang D, Lee JS, et al. Addition of Hyperbaric Oxygen Therapy vs Medical Therapy Alone for Idiopathic Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. JAMA Otolaryngology–Head & Neck Surgery. 2018;144(12):1153–1161.
Centers for Medicare & Medicaid Services. National Coverage Determination 20.29: Hyperbaric Oxygen Therapy.